Clinical Trial Update: A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial comparing pertuzumab + trastuzumab + docetaxel versus placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-09-13